- Home
- KZIA
as 11-15-2024 9:45am EST
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.
Upcoming Earnings Alert:
Get ready for potential market movements as Kazia Therapeutics Limited KZIA prepares to release earnings report on 19 Nov 2024.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | NEW SOUTH WALES 2113 |
| Market Cap: | 12.6M | IPO Year: | 1999 |
| Target Price: | $20.00 | AVG Volume (30 days): | 148.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $15.80 | Next Earning Date: | 11-19-2024 |
| Revenue: | $382 | Revenue Growth: | -94.45% |
| Revenue Growth (this year): | 4053954% | Revenue Growth (next year): | N/A |
Latest Kazia Therapeutics Limited News
KZIA Breaking Stock News: Dive into KZIA Ticker-Specific Updates for Smart Investing
PR Newswire
11 days ago
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
TipRanks
a month ago
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing
PR Newswire
a month ago
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting
PR Newswire
2 months ago
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
MT Newswires
2 months ago
Kazia Therapeutics Executes Deal With QIMR Berghofer Medical to Obtain Intellectual Property License
PR Newswire
2 months ago
KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
Zacks
4 months ago
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Clinical Trials Arena
4 months ago
Kazia Therapeutics stocks soar following Phase II/III win
Compare KZIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZIA Kazia Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.